Brief: Vistagen Receives Notice From European Patent Office Of Intention To Grant Patent For AV-101
27/12/2023 13:36
Dec 27 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN RECEIVES NOTICE FROM EUROPEAN PATENT OFFICE OF
INTENTION TO GRANT PATENT FOR AV-101 TO TREAT NEUROPATHIC PAIN
* VISTAGEN THERAPEUTICS INC - PLANS TO SEEK POTENTIAL
STRATEGIC
COLLABORATIONS TO FURTHER ADVANCE CLINICAL DEVELOPMENT AND
COMMERCIALIZATION OF AV-101
Source text for Eikon: ID:nBw1xxLpza
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors